Resveratrol as a protective molecule for neuroinflammation: A review of mechanisms

Current Pharmaceutical Biotechnology

Volumn 15, Issue 4, 2014, Pages 318-329

  Renaud, Justine ^a   Martinoli, Maria Grazia ^a,b  

^a UNIVERSITÉ DU QUÉBEC À TROIS RIVIÈRES   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Microglia; Neurodegeneration; Neuroinflammation; Neuroprotection; Polyphenols; Resveratrol

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OXIDOPAMINE; REACTIVE OXYGEN METABOLITE; RESVERATROL; SIRTUIN 1; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; SUPPRESSOR OF CYTOKINE SIGNALING 1; AMYLOID BETA PROTEIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; CYCLIC AMP; CYCLOOXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MYELOPEROXIDASE; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN E2; PROTEIN KINASE B; STAT PROTEIN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; NEUROPROTECTIVE AGENT; STILBENE DERIVATIVE;

AMYLOIDOSIS; ANTIINFLAMMATORY ACTIVITY; ASTROCYTE; BRAIN INJURY; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL (TOPIC); COCULTURE; DEGENERATIVE DISEASE; DRUG SCREENING; EPILEPTIC STATE; HOMEOSTASIS; HUMAN; MICROGLIAL CELL CULTURE; MIXED CELL CULTURE; MOLECULAR INTERACTION; MONOCULTURE; NERVE CELL NECROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHOSPHORYLATION; REPERFUSION INJURY; REVIEW; SUBSTANTIA NIGRA PARS COMPACTA; AMYLOID NEUROPATHY; ARTICLE; BRAIN CELL CULTURE; DISEASE MODEL; HUNTINGTON CHOREA; MOUSE MODEL; NERVE CELL CULTURE; NERVE CELL DEGENERATION; OLIGOMERIZATION; OXIDATIVE STRESS; PROTEIN PHOSPHORYLATION; ANIMAL; BIOLOGICAL MODEL; INFLAMMATION; METABOLISM; NEURODEGENERATIVE DISEASES;

ANIMALS; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; STILBENES;

EID: 84907349588     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201015666140617101332     Document Type: Review

References (155)

1. Kreutzberg, G.W. Microglia: A sensor for pathological events in the CNS. Trends Neurosci., 1996, 19(8), 312-318.
2. Hanisch, U.K.; Kettenmann, H. Microglia: Active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci., 2007, 10(11), 1387-1394.
3. Davalos, D.; Grutzendler, J.; Yang, G.; Kim, J.V.; Zuo, Y.; Jung, S.; Littman, D.R.; Dustin, M.L.; Gan, W.B. ATP mediates rapid microglial response to local brain injury in vivo. Nat. Neurosci., 2005, 8(6), 752-758.
4. Block, M.L.; Zecca, L.; Hong, J.S. Microglia-mediated neurotoxicity: Uncovering the molecular mechanisms. Nat. Rev. Neurosci., 2007, 8(1), 57-69.
5. Wyss-Coray, T.; Mucke, L. Inflammation in neurodegenerative disease-A double-edged sword. Neuron, 2002, 35(3), 419-432.
6. Rudge, J.S.; Morrissey, D.; Lindsay, R.M.; Pasnikowski, E.M. Regulation of ciliary neurotrophic factor in cultured rat hippocampal astrocytes. Eur. J. Neurosci., 1994, 6(2), 218-229.
7. Hatten, M.E.; Liem, R.K.; Shelanski, M.L.; Mason, C.A. Astroglia in CNS injury. Glia, 1991, 4(2), 233-243.
8. Vilcek, J. The cytokines: An overview. In: Angus W, Thomson MTL, editors. The Cytokine Handbook. 4th edition. San Diego, Calif, USA: Academic Press, 2003; pp. 1-18.
9. Ramesh, G.; MacLean, A.G.; Philipp, M.T. Cytokines and chemokines at the crossroads of neuroinflammation, neuroegeneration, and neuropathic pain. Mediators Inflamm., 2013, 2013, 480739.
10. Cámara-Lemarroy, C.R.; Guzmán-de, F.J.; Fernández-Garza, N.E. Molecular inflammatory mediators in peripheral nerve degeneration and regeneration. Neuroimmunomodulation, 2010, 17(5), 314-324.
11. Manach, C.; Scalbert, A.; Morand, C.; Rémésy, C.; Jiménez, L. Polyphenols: Food sources and bioavailability. Am. J. Clin. Nutr., 2004, 79(5), 727-47.
12. Leonard, S.S.; Xia, C.; Jiang, B.H.; Stinefelt, B.; Klandorf, H.; Harris, G.K.; Shi, X. Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem. Biophys. Res. Commun., 2003, 309(4), 1017-26.
13. Wu, J.M.; Hsieh, T.C.; Wang, Z. Cardioprotection by resveratrol: A review of effects/targets in cultured cells and animal tissues. Am. J. Cardiovasc. Dis., 2011, 1(1), 38-47.
14. Švajger, U.; Jeras, M. Anti-inflammatory effects of resveratrol and its potential use in therapy of immune-mediated diseases. Int. Rev. Immunol., 2012, 31(3), 202-222.
15. Das, S.; Das, D.K. Anti-inflammatory responses of resveratrol. Inflamm. Allerg. Drug Targets, 2007, 6(3), 168-173.
16. Renaud, J.; Bournival, J.; Zottig, X.; Martinoli, M.G. Resveratrol protects DAergic PC12 cells from high glucose-induced oxidative stress and apoptosis: Effect on p53 and GRP75 localization. Neurotox. Res., 2014, 25(1), 110-123.
17. Bournival, J.; Quessy, P.; Martinoli, M.G. Protective effects of resveratrol and quercetin against MPP+ -induced oxidative stress act by modulating markers of apoptotic death in dopaminergic neurons. Cell. Mol. Neurobiol., 2009, 29(8), 1169-1180.
18. Lin, T.K.; Chen, S.D.; Chuang, Y.C.; Lin, H.Y.; Huang, C.R.; Chuang, J.H.; Wang, P.W.; Huang, S.T.; Tiao, M.M.; Chen, J.B.; Liou, C.W. Resveratrol partially prevents rotenone-induced neurotoxicity in dopaminergic SH-SY5Y cells through induction of heme oxygenase-1 dependent autophagy. Int. J. Mol. Sci., 2014, 15(1), 1625-1646.
19. Lu, X.; Xu, H.; Sun, B.; Zhu, Z.; Zheng, D.; Li, X. Enhanced neuroprotective effects of resveratrol delivered by nanoparticles on hydrogen peroxide-induced oxidative stress in rat cortical cell culture. Mol. Pharm., 2013, 10(5), 2045-2053.
20. Blanchet, J.; Longpré, F.; Bureau, G.; Morissette, M.; DiPaolo, T.; Bronchti, G.; Martinoli, M.G. Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2008, 32(5), 1243-1250.
21. Saleh, M.C.; Connell, B.J.; Saleh, T.M. Resveratrol induced neuroprotection is mediated via both estrogen receptor subtypes, ER(α) and ER(β). Neurosci. Lett., 2013, 548, 217-221.
22. Varamini, B.; Sikalidis, A.K.; Bradford, K.L. Resveratrol increases cerebral glycogen synthase kinase phosphorylation as well as protein levels of drebrin and transthyretin in mice: an exploratory study. Int. J. Food. Sci. Nutr., 2014, 65(1), 89-96.
23. Saleh, M.C.; Connell, B.J.; Rajagopal, D.; Khan, B.V.; Abd-El- Aziz, A.S.; Kucukkaya, I.; Saleh, T.M. Co-administration of resveratrol and lipoic Acid, or their synthetic combination, enhancesneuroprotection in a rat model of ischemia/reperfusion. PLoS One, 2014, 9(1), e87865.
24. Zhang, F.; Liu, J.; Shi, J.S. Anti-inflammatory activities of resveratrol in the brain: Role of resveratrol in microglial activation. Eur. J. Pharmacol., 2010, 636(1-3), 1-7.
25. Choi DK, Koppula S, Suk, K. Inhibitors of microglial neurotoxicity: Focus on natural products. Molecules, 2011, 16(2), 1021-1043.
26. Cottart, C.H.; Nivet-Antoine, V.; Laguillier-Morizot, C.; Beaudeux, J.L. Resveratrol bioavailability and toxicity in humans. Mol. Nutr. Food Res., 2010, 54(1), 7-16.
27. Wang, Q.; Xu, J.; Rottinghaus, G.E.; Simonyi, A.; Lubahn, D.; Sun, G.Y.; Sun, A.Y. Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res., 2002, 958(2), 439-447.
28. Vingtdeux, V.; Giliberto, L.; Zhao, H.; Chandakkar, P.; Wu, Q.; Simon, J.E.; Janle, E.M.; Lobo, J.; Ferruzzi, M.G.; Davies, P.; Marambaud, P. AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J. Biol. Chem., 2010, 285(12), 9100-9113.
29. Karuppagounder, S.S.; Pinto, J.T.; Xu, H.; Chen, H.L.; Beal, M.F.; Gibson, G.E. Dietary supplementation with resveratrol reduces plaque pathology in a transgenicmodel of Alzheimer's disease. Neurochem. Int., 2009, 54(2), 111-8.
30. Mokni, M.; Elkahoui, S.; Limam, F.; Amri, M.; Aouani, E. Effect of resveratrol on antioxidant enzyme activities in the brain of healthy rat. Neurochem. Res., 2007, 32(6), 981-987.
31. Foresti, R.; Bains, S.K.; Pitchumony, T.S.; de, L.E.; Drago, F.; Dubois-Randé, J.L.; Bucolo, C.; Motterlini, R. Small molecule activators of the Nrf2-HO-1 antioxidant axis modulate heme metabolism and inflammation in BV2microglia cells. Pharmacol. Res. 2013, 76, 132-148.
32. Bournival, J.; Plouffe, M.; Renaud, J.; Provencher, C.; Martinoli, M.G. Quercetin and sesamin protect dopaminergic cells from MPP+-induced neuroinflammation in a microglial (N9)-neuronal (PC12) coculture system. Oxid. Med. Cell Longev., 2012, 2012, 921941.
33. Kumawat, K.L.; Kaushik, D.K.; Goswami, P.; Basu, A. Acute exposure to lead acetate activates microglia and induces subsequent bystander neuronal death via caspase-3 activation. Neurotoxicology, 2014, Epub ahead of print.
34. Abraham, J.; Johnson, R.W. Consuming a diet supplemented with resveratrol reduced infection-related neuroinflammation and deficits in working memory in aged mice. Rejuvenation Res., 2009, 12(6), 445-443.
35. Zhong, L.M.; Zong, Y.; Sun, L.; Guo, J.Z.; Zhang, W.; He, Y.; Song, R.; Wang, W.M.; Xiao, C.J.; Lu, D. Resveratrol inhibits inflammatory responses via the mammalian target of rapamycin signaling pathway in cultured LPS-stimulated microglial cells. PLoS One, 2012, 7(2), e32195.
36. Bi, X.L.; Yang, J.Y.; Dong, Y.X.; Wang, J.M.; Cui, Y.H.; Ikeshima, T.; Zhao, Y.Q.; Wu, C.F. Resveratrol inhibits nitric oxide and TNF-alpha production by lipopolysaccharide-activated microglia. Int. Immunopharmacol., 2005, 5(1), 185-193.
37. Candelario-Jalil, E.; Oliveira, A.C.; Gräf, S.; Bhatia, H.S.; Hüll, M.; Muñoz, E.; Fiebich, B.L. Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide- activated primary rat microglia. J. Neuroinflammation. 2007, 10, 4-25.
38. Bureau, G.; Longpré, F.; Martinoli, M.G. Resveratrol and quercetin, two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation. J. Neurosci. Res., 2008, 86(2), 403-410.
39. Ye, J.; Liu, Z.; Wei, J.; Lu, L.; Huang, Y.; Luo, L.; Xie, H. Protective effect of SIRT1 on toxicity of microglial-derived factors induced by LPS to PC12 cells via the p53-caspase-3-dependent apoptotic pathway. Neurosci. Lett., 2013, 553, 72-77.
40. Zhang, F.; Wang, H.; Wu, Q.; Lu, Y.; Nie, J.; Xie, X.; Shi, J. Resveratrol protects cortical neurons against microglia-mediated neuroinflammation. Phytother. Res., 2013, 27(3), 344-349.
41. Zhang, F.; Shi, J.S.; Zhou, H.; Wilson, B.; Hong, J.S.; Gao, H.M. Resveratrol protects dopamine neurons against lipopolysaccharideinduced neurotoxicity through its anti-inflammatory actions. Mol. Pharmacol., 2010, 78(3), 466-477.
42. Chen, J.; Zhou, Y.; Mueller-Steiner, S.; Chen, L.F.; Kwon, H.; Yi, S.; Mucke, L.; Gan, L. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J. Biol. Chem., 2005, 280(48), 40364-40374.
43. Capiralla, H.; Vingtdeux, V.; Zhao, H.; Sankowski, R.; Al-Abed, Y.; Davies, P.; Marambaud, P. Resveratrol mitigates lipopolysaccharide- and A β-mediated microglial inflammation by inhibiting theTLR4/NF-κB/STAT signaling cascade. J. Neurochem. 2012, 120(3), 461-472.
44. Frozza, R.L.; Bernardi, A.; Hoppe, J.B.; Meneghetti, A.B.; Battastini, A.M.; Pohlmann, A.R.; Guterres, S.S.; Salbego, C. Lipidcore nanocapsules improve the effects of resveratrol against Abetainduced neuroinflammation. J. Biomed. Nanotechnol., 2013, 9(12), 2086-2104.
45. Kim, Y.A.; Kim, G.Y.; Park, K.Y.; Choi, Y.H. Resveratrol inhibits nitric oxide and prostaglandin E2 production by lipopolysaccharide- activated C6 microglia. J. Med. Food, 2007, 10(2), 218-224.
46. Lu, X.; Ma, L.; Ruan, L.; Kong, Y.; Mou, H.; Zhang, Z.; Wang, Z.; Wang, J.M.; Le, Y. Resveratrol differentially modulates inflammatory responses of microglia and astrocytes. J. Neuroinflammation, 2010, 7, 46.
47. Wight, R.D.; Tull, C.A.; Deel, M.W.; Stroope, B.L.; Eubanks, A.G.; Chavis, J.A.; Drew, P.D.; Hensley, L.L. Resveratrol effects on astrocyte function: Relevance to neurodegenerative diseases. Biochem. Biophys. Res. Commun., 2012, 426(1), 112-115.
48. Bellaver, B.; Souza, D.G.; Souza, D.O.; Quincozes-Santos, A. Resveratrol increases antioxidant defenses and decreases proinflammatory cytokines in hippocampal astrocyte cultures from newborn, adult and aged Wistar rats. Toxicol. In Vitro, 2014, 28(4), 479-484.
49. Meng, X.L.; Yang, J.Y.; Chen, G.L.; Wang, L.H.; Zhang, L.J.; Wang, S.; Li, J.; Wu, C.F. Effects of resveratrol and its derivatives on lipopolysaccharide-induced microglial activation and their structureactivity relationships. Chem. Biol. Interact., 2008, 174(1), 51-59.
50. Heynekamp, J.J.; Weber, W.M.; Hunsaker, L.A.; Gonzales, A.M.; Orlando, R.A.; Deck, L.M.; Jagt, D.L. Substituted trans-stilbenes, including analogues of the natural product resveratrol, inhibit the human tumor necrosis factor alpha-induced activation of transcription factor nuclear factor kappaB. J. Med. Chem., 2006, 49(24), 7182-7189.
51. Hauss, F.; Liu, J.; Michelucci, A.; Coowar, D.; Morga, E.; Heuschling, P.; Luu, B. Dual bioactivity of resveratrol fatty alcohols: differentiation of neural stem cells and modulation of neuroinflammation. Bioorg. Med. Chem. Lett., 2007, 17(15), 4218-4222.
52. Gao, H.M.; Hong, J.S. Why neurodegenerative diseases are progressive: Uncontrolled inflammation drives disease progression. Trends Immunol., 2008, 29(8), 357-365.
53. Codolo, G.; Plotegher, N.; Pozzobon, T.; Brucale, M.; Tessari, I.; Bubacco, L.; Bernard, M. Triggering of inflammasome by aggregated α-synuclein, An inflammatory response in synucleinopathies. PLoS One, 2013, 8(1), e55375.
54. Alvarez-Erviti, L.; Couch, Y.; Richardson, J.; Cooper, J.M.; Wood, M.J. Alpha-synuclein release by neurons activates the inflammatory response in a microglial cell line. Neurosci. Res., 2011, 69(4), 337-342.
55. Roodveldt, C.; Labrador-Garrido, A.; Gonzalez-Rey, E.; Lachaud, C.C.; Guilliams, T.; Fernandez-Montesinos, R.; Benitez-Rondan, A.; Robledo, G.; Hmadcha, A.; Delgado, M.; Dobson, C.M.; Pozo, D. Preconditioning of microglia by α-synuclein strongly affects the response induced by toll-like receptor (TLR) stimulation. PLoS One, 2013, 8(11), e79160.
56. Möller, T. Neuroinflammation in Huntington's disease. J. Neural Transm., 2010, 117(8), 1001-1018.
57. Zhang, W.; Wang, T.; Pei, Z.; Miller, D.S.; Wu, X.; Block, M.L.; Wilson, B.; Zhang, W.; Zhou, Y.; Hong, J.S.; Zhang, J. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB. J., 2005, 19(6), 533-542.
58. Floden, A.M.; Li, S.; Combs, C.K. Beta-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alphaand NMDA receptors. J. Neurosci., 2005, 25(10), 2566-2575.
59. Cui, G.; Wang, H.; Li, R.; Zhang, L.; Li, Z.; Wang, Y.; Hui, R.; Ding, H.; Wang, D.W. Polymorphism of tumor necrosis factor alpha (TNF-alpha) gene promoter, circulating TNF-alpha level, and cardiovascular risk factor for ischemic stroke. J. Neuroinflammation, 2012, 9, 235.
60. Heun, R.; Kölsch, H.; Ibrahim-Verbaas, C.A.; Combarros, O.; Aulchenko, Y.S.; Breteler, M.; Schuur, M.; Duijn, C.M.; Hammond, N.; Belbin, O.; Cortina-Borja, M.; Wilcock, G.K.; Brown, K.; Barber, R.; Kehoe, P.G.; Coto, E.; Alvarez, V.; Lehmann, M.G.; Deloukas, P.; Mateo, I.; Morgan, K.; Warden, D.; Smith, A.D.; Lehmann, D.J. Interactions between PPAR-α and inflammation- related cytokine genes on the development of Alzheimer's disease, observed by the Epistasis Project. Int. J. Mol. Epidemiol. Genet., 2012, 3(1), 39-47.
61. Yu, J.T.; Mou, S.M.; Wang, L.Z.; Mao, C.X.; Tan, L. Toll-like receptor 2 -196 to -174 del polymorphism influences the suscepti bility of Han Chinese people to Alzheimer's disease. J. Neuroinflammation, 2011, 8, 136.
62. Pascale, E.; Passarelli, E.; Purcaro, C.; Vestri, A.R.; Fakeri, A.; Guglielmi, R.; Passarelli, F.; Meco, G. Lack of association between IL-1β, TNF-α, and IL-10 gene polymorphisms and sporadic Parkinson's disease in an Italian cohort. Acta. Neurol. Scand., 2011, 124(3), 176-181.
63. Combarros, O.; Duijn, C.M.; Hammond, N.; Belbin, O.; Arias- Vásquez, A.; Cortina-Borja, M.; Lehmann, M.G.; Aulchenko, Y.S.; Schuur, M.; Kölsch, H.; Heun, R.; Wilcock, G.K.; Brown, K.; Kehoe, P.G.; Harrison, R.; Coto, E.; Alvarez, V.; Deloukas, P.; Mateo, I.; Gwilliam, R.; Morgan, K.; Warden, D.R.; Smith, A.D.; Lehmann, D.J. Replication by the Epistasis Project of the interaction between the genes for IL-6 and IL-10 in the risk of Alzheimer's disease. J. Neuroinflammation, 2009, 6, 22.
64. Wahner, A.D.; Sinsheimer, J.S.; Bronstein, J.M.; Ritz, B. Inflammatory cytokine gene polymorphisms and increased risk of Parkinson disease. Arch. Neurol., 2007, 64(6), 836-840.
65. Zhao, N.; Liu, X.; Wang, Y.; Liu, X.; Li, J.; Yu, L.; Ma, L.; Wang, S.; Zhang, H.; Liu, L.; Zhao, J.; Wang, X. Association of inflammatory gene polymorphisms with ischemic stroke in a Chinese Han population. J. Neuroinflammation, 2012, 9, 162.
66. McGeer, P.L.; Itagaki, S.; Boyes, B.E.; McGeer, E. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology, 1988, 38(8), 1285-1291.
67. Lofrumento, D.D.; Nicolardi, G.; Cianciulli, A.; De Nuccio, F.; Pesa, V.; Carofiglio, V.; Dragone, T.; Calvello, R.; Panaro, M.A. Neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson's-like disease: Possible role of SOCS-1 in reducing proinflammatory responses. Innate Immun., 2014, 20(3), 249-260.
68. Jin, F.; Wu, Q.; Lu, Y.F.; Gong, Q.H.; Shi, J.S. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats. Eur. J. Pharmacol., 2008, 600(1-3), 78-82.
69. Solberg, N.O.; Chamberlin, R.; Vigil, J.R.; Deck, L.M.; Heidrich, J.E.; Brown, D.C.; Brady, C.I.; Vander, T.A.; Garwood, M.; Bisoffi, M.; Severns, V.; Vander, Jagt, D.L.; Sillerud, L.O. Optical and SPION-Enhanced MR Imaging Shows that trans-Stilbene Inhibitors of NF-κB Concomitantly Lower Alzheimer's Disease Plaque Formation and Microglial Activation in AβPP/PS-1 Transgenic Mouse Brain. J. Alzheimers Dis., 2014,
70. Zaky, A.; Mohammad, B.; Moftah, M.; Kandeel, K.M.; Bassiouny, A.R. Apurinic/apyrimidinic endonuclease 1 is a key modulator of aluminum-induced neuroinflammation. BMC. Neurosci., 2013, 14, 26.
71. Maher, P.; Dargusch, R.; Bodai, L.; Gerard, P.E.; Purcell, J.M.; Marsh, J.L. ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease. Hum. Mol. Genet., 2011, 20(2), 261-70.
72. Ziebell, J.M.; Morganti-Kossmann, M.C. Involvement of pro- and anti-inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury. Neurotherapeutics, 2010, 7(1), 22-30.
73. David, S.; López-Vales, R.; Yong, V. Harmful and beneficial effects of inflammation after spinal cord injury: Potential therapeutic implications. Handb. Clin. Neurol., 2012, 109, 485-502.
74. Amantea, D.; Nappi, G.; Bernardi, G.; Bagetta, G.; Corasaniti, M.T. Post-ischemic brain damage: Pathophysiology and role of inflammatory mediators. FEBS. J., 2009, 276(1), 13-26.
75. Spuy, W.J.; Pretorius, E. Interrelation between inflammation, thrombosis, and neuroprotection in cerebral ischemia. Rev. Neurosci., 2012, 23(3), 269-278.
76. Janigro, D.; Iffland, P.H.; Marchi, N.; Granata, T. A role for inflammation in status epilepticus is revealed by a review of current therapeutic approaches. Epilepsia, 2013, 54(Suppl 6), 30-32.
77. Benowitz, L.I, Popovich, P.G. Inflammation and axon regeneration. Curr. Opin. Neurol., 2011, 24(6), 577-583.
78. Max, J.E. Neuropsychiatry of Pediatric Traumatic Brain Injury. Psychiatr. Clin. North Am., 2014, 37(1), 125-140.
79. Gatson, J.W.; Liu, M.M.; Abdelfattah, K.; Wigginton, J.G.; Smith, S.; Wolf, S.; Minei, J.P. Resveratrol decreases inflammation in the brain of mice with mild traumatic brain injury. J. Trauma Acute Care Surg., 2013, 74(2), 470-4; discussion 474-475.
80. Liu, C.; Shi, Z.; Fan, L.; Zhang, C.; Wang, K.; Wang, B. Resveratrol improves neuron protection and functional recovery in rat model of spinal cord injury. Brain Res., 2011, 1374, 100-109.
81. Simão, F.L.; Matté, A.; Pagnussat, A.S.; Netto, C.A.; Salbego, C.G. Resveratrol preconditioning modulates inflammatory response in the rat hippocampus following global cerebral ischemia. Neurochem. Int., 2012, 61(5), 659-665.
82. Wang, S.J.; Bo, Q.Y.; Zhao, X.H.; Yang, X.; Chi, Z.F.; Liu, X.W. Resveratrol pre-treatment reduces early inflammatory responses induced by status epilepticus via mTOR signaling. Brain Res., 2013, 1492, 122-129.
83. Zhang, X.; Zhang, G.; Zhang, H.; Karin, M.; Bai, H.; Cai, D. Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. Cell, 2008, 135(1), 61-73.
84. Souza, C.T.; Araujo, E.P.; Bordin, S.; Ashimine, R.; Zollner, R.L.; Boschero, A.C.; Saad, M.J.; Velloso, L.A. Consumption of a fatrich diet activates a proinflammatory response and induces insulin resistance in the hypothalamus. Endocrinology, 2005, 146(10), 4192-4199.
85. Purkayastha, S.; Cai, D. Neuroinflammatory basis of metabolic syndrome. Mol. Metab., 2013, 2(4), 356-363.
86. Thaler, J.P.; Guyenet, S.J.; Dorfman, M.D.; Wisse, B.E.; Schwartz, M.W. Hypothalamic inflammation: Marker or mechanism of obesity pathogenesis. Diabetes, 2013, 62(8), 2629-2634.
87. Cai, D. Neuroinflammation and neurodegeneration in overnutrition- induced diseases. Trends Endocrinol. Metab., 2013, 24(1), 40-47.
88. Thaler, J.P.; Yi, C.X.; Schur, E.A.; Guyenet, S.J.; Hwang, B.H.; Dietrich, M.O.; Zhao, X.; Sarruf, D.A.; Izgur, V.; Maravilla, K.R.; Nguyen, H.T.; Fischer, J.D.; Matsen, M.E.; Wisse, B.E.; Morton, G.J.; Horvath, T.L.; Baskin, D.G.; Tschöp, M.H.; Schwartz, M.W. Obesity is associated with hypothalamic injury in rodents and humans. J. Clin. Invest., 2012, 122(1), 153-162.
89. Dash, S.; Xiao, C.; Morgantini, C.; Szeto, L.; Lewis, G.F. Highdose resveratrol treatment for 2 weeks inhibits intestinal and hepatic lipoprotein production in overweight/obese men. Arterioscler. Thromb. Vasc. Biol., 2013, 33(12), 2895-2901.
90. Bhatt, J.K.; Thomas, S.; Nanjan, M.J. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr. Res., 2012, 32(7), 537-541.
91. Tomé-Carneiro, J.; Larrosa, M.; Yáñez-Gascón, M.J.; Dávalos, A.; Gil-Zamorano, J.; Gonzálvez, M.; García-Almagro, F.J.; Ruiz, J.A.; Tomás-Barberán, F.A.; Espín, JC, García-Conesa, M.T. One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacol. Res., 2013, 72, 69-82.
92. Tomé-Carneiro, J.; Gonzálvez, M.; Larrosa, M.; Yáñez-Gascón, M.J.; García-Almagro, F.J; Ruiz-Ros, J.A.; García-Conesa, M.T.; Tomás-Barberán, F.A.; Espín, J.C. One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am. J. Cardiol., 2012, 110(3), 356-363.
93. Ramadori, G.; Gautron, L.; Fujikawa, T.; Vianna, C.R.; Elmquist, J.K.; Coppari, R. Central administration of resveratrol improves diet-induced diabetes. Endocrinology, 2009, 150(12), 5326-5333.
94. Jeon, B.T.; Jeong, E.A.; Shin, H.J.; Lee, Y.; Lee, D.H.; Kim, H.J.; Kang, S.S.; Cho, G.J.; Choi, W.S.; Roh, G.S. Resveratrol attenuates obesity-associated peripheral and central inflammation and improves memory deficit in mice fed a high-fat diet. Diabetes, 2012, 61(6), 1444-1454.
95. Spasić, M.R.; Callaerts, P.; Norga, K.K. AMP-activated protein kinase (AMPK) molecular crossroad for metabolic control and survival of neurons. Neuroscientist, 2009, 15(4), 309-316.
96. Salminen, A.; Hyttinen, J.M.; Kaarniranta, K. AMP-activated protein kinase inhibits NF-κB signaling and inflammation: Impact on healthspan andlifespan. J. Mol. Med. (Berl), 2011, 89(7), 667-676.
97. Thomas, J.; Garg, M.L.; Smith, D.W. Dietary resveratrol supplementation normalizes gene expression in the hippocampus of streptozotocin- induced diabetic C57Bl/6 mice. J. Nutr. Biochem., 2014, 25(3), 313-318.
98. Hou, X.; Xu, S.; Maitland-Toolan, K.A.; Sato, K.; Jiang, B.; Ido, Y.; Lan, F.; Walsh, K.; Wierzbicki, M.; Verbeuren, T.J.; Cohen, R.A.; Zang, M. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J. Biol. Chem., 2008, 283(29), 20015-20026.
99. Lan, F.; Cacicedo, J.M.; Ruderman, N.; Ido, Y. SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. J. Biol. Chem., 2008, 283(41), 27628-27635.
100. Howitz, K.T.; Bitterman, K.J.; Cohen, H.Y.; Lamming, D.W.; Lavu, S.; Wood, J.G.; Zipkin, R.E.; Chung, P.; Kisielewski, A.; Zhang, L.L.; Scherer, B.; Sinclair, D.A. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature, 2003, 425(6954), 191-196.
101. Dai, H.; Kustigian, L.; Carney, D.; Case, A.; Considine, T.; Hubbard, B.P.; Perni, R.B.; Riera, T.V.; Szczepankiewicz, B.; Vlasuk, G.P.; Stein, R.L. SIRT1 activation by small molecules: Kinetic and biophysical evidence for direct interaction of enzyme and activator. J. Biol. Chem., 2010, 285(43), 32695-32703.
102. Beher, D.; Wu, J.; Cumine, S.; Kim, K.W.; Lu, S.C.; Atangan, L.; Wang, M. Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem. Biol. Drug Des., 2009, 74(6), 619-624.
103. Kaeberlein, M.; Kirkland, K.T.; Fields, S.; Kennedy, B.K. Sir2- independent life span extension by calorie restriction in yeast. PLoS Biol., 2004, 2, E296.
104. Borra, M.T.; Smith, B.C.; Denu, J.M. Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem., 2005, 280(17), 17187-17195.
105. Pacholec, M.; Bleasdale, J.E.; Chrunyk, B.; Cunningham, D.; Flynn, D.; Garofalo, R.S.; Griffith, D.; Griffor, M.; Loulakis, P.; Pabst, B.; Qiu, X.; Stockman, B.; Thanabal, V.; Varghese, A.; Ward, J.; Withka, J.; Ahn, K. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J. Biol. Chem., 2010, 285(11), 8340-51.
106. Hubbard, B.P.; Gomes, A.P.; Dai, H.; Li, J.; Case, A.W.; Considine, T.; Riera, T.V; Lee, J.E.; Lamming, D.W.; Pentelute, B.L.; Schuman, E.R.; Stevens, L.A.; Ling, A.J.; Armour, S.M.; Michan, S.; Zhao, H.; Jiang, Y.; Sweitzer, S.M.; Blum, C.A.; Disch, J.S.; Ng, P.Y.; Howitz, K.T.; Rolo, A.P.; Hamuro, Y.; Moss, J.; Perni, R.B.; Ellis, J.L.; Vlasuk, G.P.; Sinclair, D.A. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Sci., 2013, 339(6124), 1216-1219.
107. Lakshminarasimhan, M.; Rauh, D.; Schutkowski, M.; Steegborn, C. Sirt1 activation by resveratrol is substrate sequence-selective. Aging (Albany NY)., 2013, 5(3), 151-154.
108. Park, S.J.; Ahmad, F.; Philp, A.; Baar, K.; Williams, T.; Luo, H.; Ke, H.; Rehmann, H.; Taussig, R.; Brown, A.L.; Kim, M.; Beaven, M.A.; Burgin, A.B.; Manganiello, V.; Chung, J.H. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell, 2012, 148(3), 421-433.
109. Cantó, C.; Gerhart-Hines, Z.; Feige, J.N.; Lagouge, M.; Noriega, L.; Milne, J.C.; Elliott, P.J.; Puigserver, P.; Auwerx, J. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature, 2009, 458(7241), 1056-1060.
110. Price, N.L.; Gomes, A.P.; Ling, A.J.; Duarte, F.V; Martin- Montalvo, A.; North, B.J; Agarwal, B.; Ye, L.; Ramadori, G.; Teodoro, J.S.; Hubbard, B.P; Varela, A.T; Davis, J.G.; Varamini, B.; Hafner, A.; Moaddel, R.; Rolo, A.P.; Coppari, R.; Palmeira, C.M.; Cabo, R.; Baur, J.A.; Sinclair, D.A. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab., 2012, 15(5), 675-690.
111. Yeung, F.; Hoberg, J.E.; Ramsey, C.S.; Keller, M.D.; Jones, D.R.; Frye, R.A.; Mayo, M.W. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO. J., 2004, 23(12), 2369-2380.
112. Donadini, A.; Rosano, C.; Felli, L.; Ponassi, M. Human sirtuins: An overview of an emerging drug target in age-related diseases and cancer. Curr. Drug Targets, 2013, 14(6), 653-661.
113. Gillum, M.P.; Kotas, M.E; Erion, D.M.; Kursawe, R.; Chatterjee, P.; Nead, K.T.; Muise, E.S.; Hsiao, J.J.; Frederick, D.W. SirT1 regulates adipose tissue inflammation. Diab., 2011, 60(12), 3235-3245.
114. Schug, T.T.; Xu, Q.; Gao, H.; Peres-da-Silva, A.; Draper, D.W.; Fessler, M.B.; Purushotham, A.; Li, X. Myeloid deletion of SIRT1 induces inflammatory signaling in response to environmental stress. Mol. Cell. Biol., 2010, 30(19), 4712-4721.
115. Xu, F.; Gao, Z.; Zhang, J.; Rivera, C.A.; Yin, J.; Weng, J.; Ye, J. Lack of SIRT1 (Mammalian Sirtuin 1) activity leads to liver steatosis in the SIRT1+/- mice: A role of lipid mobilization and inflammation. Endocrinology, 2010, 151(6), 2504-2514.
116. Ghosh, M.; Garcia-Castillo, D.; Aguirre, V.; Golshani, R.; Atkins, C.M.; Bramlett, H.; Dietrich, W.D.; Pearse, D.D. Proinflammatory cytokine regulation of cyclic AMP-phosphodiesterase 4 signaling in microglia in vitro and following CNS injury. Glia, 2012, 60(12), 1839-1859.
117. Zhao, X.; Zmijewski, J.; Lorne, E.; Liu, G.; Park, Y.J.; Tsuruta, Y.; Abraham, E. Activation of AMPK attenuates neutrophil proinflammatory activity and decreases the severity of acute lung injury. Am. J. Physiol. Lung Cell Mol. Physiol., 2008, 295(3), L497-504.
118. Youn, H.S.; Saitoh, S.I.; Miyake, K.; Hwang, D.H. Inhibition of homodimerization of Toll-like receptor 4 by curcumin. Biochem. Pharmacol., 2006, 72(1), 62-69.
119. McCarty, M.F.; Barroso-Aranda, J.; Contreras, F. AMP-activated kinase may suppress NADPH oxidase activation in vascular tissues. Med. Hypotheses., 2009, 72(4), 468-470.
120. Song, P.; Zou, M.H. Regulation of NAD(P)H oxidases by AMPK in cardiovascular systems. Free Radic. Biol. Med., 2012, 52(9), 1607-1619.
121. Tang, H.; Pan, C.S.; Mao, X.W.; Liu, Y.Y.; Yan, L.; Zhou, C.M.; Fan, J.Y.; Zhang, S.Y.; Han, J.Y. Role of NADPH oxidase in total salvianolic acid injection attenuating ischemia-reperfusion impaired cerebral microcirculation and neurons: implication of AMPK/Akt/PKC. Microcirculation, 2014, Epub ahead of print.
122. Yamamori, T.; DeRicco, J.; Naqvi, A.; Hoffman, T.A.; Mattagajasingh, I.; Kasuno, K.; Jung, S.B.; Kim, C.S; Irani, K. SIRT1 deacetylates APE1 and regulates cellular base excision repair. Nucleic Acids Res., 2010, 38(3), 832-845.
123. Venkatasubramanian, S.; Noh, R.M.; Daga, S.; Langrish, J.P.; Joshi, N.V; Mills, N.L.; Hoffmann, E.; Jacobson, E.W.; Vlasuk, G.P. Waterhouse, B.R. Cardiovascular effects of a novel SIRT1 activator, SRT2104, in otherwise healthy cigarette smokers. J. Am. Heart Assoc., 2013, 2(3), e000042.
124. Gräff, J.; Kahn, M.; Samiei, A.; Gao, J.; Ota, K.T.; Rei, D.; Tsai, L.H. A dietary regimen of caloric restriction or pharmacological activation of SIRT1 to delay the onset of neurodegeneration. J. Neurosci., 2013, 33(21), 8951-8960.
125. Libri, V.; Brown, A.P.; Gambarota, G.; Haddad, J.; Shields, G.S.; Dawes, H.; Pinato, D.J.; Hoffman, E.; Elliot, P.J.; Vlasuk, G.P. A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers. PLoS One, 2012, 7(12), e51395.
126. Hubbard, B.P.; Sinclair, D.A. Small molecule SIRT1 activators for the treatment of aging and age-related diseases. Trends Pharmacol. Sci., 2014, 35(3), 146-154.
127. Zhang, R.; Chen, H.Z.; Liu, J.J.; Jia, Y.Y.; Zhang, Z.Q.; Yang, R.F.; Zhang, Y; Xu, J.; Wei, Y.S.; Liu, D.P.; Liang, C.C. SIRT1 suppresses activator protein-1 transcriptional activity and cyclooxygenase- 2 expression in macrophages. J. Biol. Chem., 2010, 285(10), 7097-7110.
128. Burgin, A.B.; Magnusson, O.T.; Singh, J.; Witte, P.; Staker, B.L.; Bjornsson, J.M.; Thorsteinsdottir, M.; Hrafnsdottir, S.; Hagen, T.; Kiselyov, A.S.; Stewart, L.J.; Gurney, M.E. Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat. Biotechnol., 2010, 28, 63-70.
129. Smith, D.L.; Pozueta, J.; Gong, B.; Arancio, O.; Shelanski, M. Reversal of long-term dendritic spine alterations in Alzheimer disease models. Proc. Natl. Acad. Sci. USA., 2009, 106, 16877-16882.
130. Yang, L.; Calingasan, N.Y.; Lorenzo, B.J.; Beal, M.F. Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV. Exp. Neurol., 2008, 211, 311-314.
131. Hebb, A.L.; Robertson, H.A. PDEs as drug targets for CNS immune disorders. Curr. Opin. Investig. Drugs., 2008, 9(7), 744-753.
132. Sun, A.Y.; Wang, Q.; Simonyi, A.; Sun, G.Y. Resveratrol as a therapeutic agent for neurodegenerative diseases. Mol. Neurobiol., 2010, 41(2-3), 375-383.
133. Rodrigo, R.; Fernández-Gajardo, R.; Gutiérrez, R.; Matamala, J.M.; Carrasco, R.; Miranda-Merchak, A.; Feuerhake, W. Oxidative stress and pathophysiology of ischemic stroke: Novel therapeutic opportunities. CNS Neurol. Disord. Drug Targets, 2013, 12(5), 698-714.
134. Hall, E.D.; Vaishnav, R.; Mustafa, A.G. Antioxidant therapies for traumatic brain injury. Neurotherapeutics, 2010, 7(1), 51-61.
135. Barzilai, A.; Yamamoto, K. DNA damage responses to oxidative stress. DNA Repair (Amst), 2004, 3(8-9), 1109-1115.
136. Niki, E. Lipid peroxidation products as oxidative stress biomarkers. Biofactors, 2008, 34(2), 171-180.
137. Reynolds, A.; Laurie, C.; Mosley, R.L.; Gendelman, H.E. Oxidative stress and the pathogenesis of neurodegenerative disorders. In. Rev. Neurobiol., 2007, 82, 297-325.
138. Khanduja, K.L.; Bhardwaj, A. Stable free radical scavenging and antiperoxidative properties of resveratrol compared in vitro with some other bioflavonoids. Indian J. Biochem. Biophys., 2003, 40(6), 416-422.
139. Paterniti, I.; Esposito, E.; Cuzzocrea, S. Phosphodiesterases as a New Therapeutic Targets for the Treatment of Spinal Cord Injury and Neurodegenerative Diseases. Curr. Med. Chem., 2014, Epub ahead of print.
140. Sanabra, C.; Johansson, E.M.; Mengod, G. Critical role for PDE4 subfamilies in the development of experimental autoimmune encephalomyelitis. J. Chem. Neuroanat., 2013, 47, 96-105.
141. Johansson, E.M.; Sanabra, C.; Cortés, R.; Vilaró, M.T.; Mengod, G. Lipopolysaccharide administration in vivo induces differential expression of cAMP-specificphosphodiesterase 4B mRNA splice variants in the mouse brain. J. Neurosci. Res., 2011, 89(11), 1761-1772.
142. Wang, C.; Yang, X.M.; Zhuo, Y.Y.; Zhou, H.; Lin, H.B.; Cheng, Y.F.; Xu, J.P.; Zhang, H.T. The phosphodiesterase-4 inhibitor rolipram reverses Aβ-induced cognitive impairment and neuroinflammatory and apoptotic responses in rats. Int. J. Neuropsychopharmacol., 2012, 15(6), 749-766.
143. Patrizio, M. Tumor necrosis factor reduces cAMP production in rat microglia. Glia, 2004, 48(3), 241-249.
144. Walle, T. Bioavailability of resveratrol. Ann. N. Y. Acad. Sci., 2011, 1215, 9-15.
145. Delmas, D.; Aires, V.; Limagne, E.; Dutartre, P.; Mazué, F.; Ghiringhelli, F.; Latruffe, N. Transport, stability, and biological activity of resveratrol. Ann. N. Y. Acad. Sci., 2011, 1215, 48-59.
146. Maier-Salamon, A.; Böhmdorfer, M.; Riha, J.; Thalhammer, T.; Szekeres, T.; Jaeger, W. Interplay between metabolism and transport of resveratrol. Ann. N. Y. Acad. Sci., 2013, 1290, 98-106.
147. Andreadi, C.; Britton, R.G.; Patel, K.R.; Brown, K. Resveratrolsulfates provide an intracellular reservoir for generation of parent resveratrol, which induces autophagy in cancer cells. Autophagy, 2014, 10(3), 524-525.
148. Du, Q.; Hu, B.; Shen, K.P.; Xu, L.; Deng, S.; Wei, M.M. Synergistic anticancer effects of curcumin and resveratrol in Hepa1-6 hepatocellular carcinoma cells. Oncol. Rep., 2013, 29(5), 1851-1858.
149. Neves, A.R.; Lúcio, M.; Martins, S.; Lima, J.L.; Reis, S. Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability. Int. J. Nanomedicine, 2013, 8, 177-187.
150. Souto, E.B.; Severino, P.; Basso, R.; Santana, M.H. Encapsulation of antioxidants in gastrointestinal-resistant nanoparticulate carriers. Methods Mol. Biol., 2013, 1028, 37-46.
151. Augustin, M.A.; Sanguansri, L.; Lockett, T. Nano- and microencapsulated systems for enhancing the delivery of resveratrol. Ann. N. Y. Acad. Sci., 2013, 1290, 107-112.
152. Amiot, M.J.; Romier, B.; Dao, T.M.; Fanciullino, R.; Ciccolini, J.; Burcelin, R.; Pechere, L.; Emond, C.; Savouret, J.F.; Seree, E. Optimization of trans-Resveratrol bioavailability for human therapy. Biochimie, 2013, 95(6), 1233-1238.
153. Giovinazzo, G.; Ingrosso, I.; Paradiso, A.; Gara, L.; Santino, A. Resveratrol biosynthesis: Plant metabolic engineering for nutritional improvement of food. Plant Foods Hum Nutr., 2012, 67(3), 191-199.
154. Piotrowska, H.; Kucinska, M.; Murias, M. Biological activity of piceatannol: Leaving the shadow of resveratrol. Mutat Res., 2012, 750(1), 60-82.
155. Estrela, J.M.; Ortega, A.; Mena, S.; Rodriguez, M.L.; Asensi, M. Pterostilbene: biomedical applications. Crit. Rev. Clin. Lab. Sci., 2013, 50(3), 65-78.